• Login
    View Item 
    •   DSpace Home
    • Bethlehem University Faculty Research
    • Faculty of Science
    • View Item
    •   DSpace Home
    • Bethlehem University Faculty Research
    • Faculty of Science
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Immune Checkpoint Blockade Therapy for Cancer

    Thumbnail
    View/Open
    ICB therapy for Cancer.pdf (304.7Kb)
    Date
    2019-03
    Author
    Hazboun, Nader
    Metadata
    Show full item record
    Abstract
    The expression of immune checkpoint molecules such as programmed cell death ligand 1 (PD-L1) on the surface of cancer cells and programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) on the surface of T-cells results in immune tolerance. Despite the unprecedented success of checkpoint inhibitors in cancer therapy, only a minority of patients respond durably. This review focuses on the role of immune checkpoint blockade in cancer therapy highlighting clinical trials with the best results, mechanisms of resistance, combination therapies and future directions in this interesting field.
    URI
    http://dspace.bethlehem.edu:8080/xmlui/handle/123456789/106
    Collections
    • Faculty of Science [82]

    DSpace software copyright © 2002-2016  DuraSpace
    Contact Us | Send Feedback
    Theme by 
    Atmire NV
     

     

    Browse

    All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    DSpace software copyright © 2002-2016  DuraSpace
    Contact Us | Send Feedback
    Theme by 
    Atmire NV